133 related articles for article (PubMed ID: 35115094)
1. Letter to the editor regarding "Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.".
Liang R
Cancer Lett; 2022 Feb; 527():191-192. PubMed ID: 35115094
[No Abstract] [Full Text] [Related]
2. Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.
Chaudhary S; Pothuraju R; Rachagani S; Siddiqui JA; Atri P; Mallya K; Nasser MW; Sayed Z; Lyden ER; Smith L; Gupta SD; Ralhan R; Lakshmanan I; Jones DT; Ganti AK; Macha MA; Batra SK
Cancer Lett; 2021 Jul; 510():79-92. PubMed ID: 33878394
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck.
Billard-Sandu C; Tao YG; Sablin MP; Dumitrescu G; Billard D; Deutsch E
Eur Arch Otorhinolaryngol; 2020 May; 277(5):1273-1280. PubMed ID: 32162057
[TBL] [Abstract][Full Text] [Related]
4. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Zhou J; Wu Z; Wong G; Pectasides E; Nagaraja A; Stachler M; Zhang H; Chen T; Zhang H; Liu JB; Xu X; Sicinska E; Sanchez-Vega F; Rustgi AK; Diehl JA; Wong KK; Bass AJ
Nat Commun; 2017 Jan; 8():13897. PubMed ID: 28059068
[TBL] [Abstract][Full Text] [Related]
7. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
Song Q; Li X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
[TBL] [Abstract][Full Text] [Related]
8. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
9. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
van Caloen G; Machiels JP
Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
[TBL] [Abstract][Full Text] [Related]
10. EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma.
Jiang H; Luo N; Zhang X; Song C; Zang J
Lung Cancer; 2020 Jul; 145():216-218. PubMed ID: 32345450
[No Abstract] [Full Text] [Related]
11. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex.
Lei Y; Kansy BA; Li J; Cong L; Liu Y; Trivedi S; Wen H; Ting JP; Ouyang H; Ferris RL
Oncogene; 2016 Sep; 35(36):4698-707. PubMed ID: 26876213
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
13. Intriguing issues of EGFR targeting in head and neck cancer.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
Ann Oncol; 2007 May; 18(5):962. PubMed ID: 17442660
[No Abstract] [Full Text] [Related]
14. The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis.
Nie D; Wang X; Sun M; Feng Z; Pei F; Liu W; Wang Z; Han F
Radiother Oncol; 2021 May; 158():13-20. PubMed ID: 33587969
[TBL] [Abstract][Full Text] [Related]
15. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
16. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?
Jelinek MJ; Vokes EE
J Clin Oncol; 2019 Nov; 37(31):2807-2814. PubMed ID: 31483688
[No Abstract] [Full Text] [Related]
18. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Tan DSW; Chong FT; Leong HS; Toh SY; Lau DP; Kwang XL; Zhang X; Sundaram GM; Tan GS; Chang MM; Chua BT; Lim WT; Tan EH; Ang MK; Lim TKH; Sampath P; Chowbay B; Skanderup AJ; DasGupta R; Iyer NG
Nat Med; 2017 Oct; 23(10):1167-1175. PubMed ID: 28920960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
